Article
ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HE
Rating:
0.0
Views:
45
Likes:
1
Library:
1
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has received acceptance for its suppleme
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value